Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Aptevo Therapeutics Inc. (APVO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.79-0.10 (-1.70%)
At close: 04:00PM EST
5.90 +0.11 (+1.90%)
After hours: 06:36PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.89
Open5.27
Bid5.56 x 1000
Ask5.90 x 900
Day's Range5.26 - 5.86
52 Week Range4.74 - 43.21
Volume71,821
Avg. Volume3,569,466
Market Cap28.36M
Beta (5Y Monthly)6.70
PE Ratio (TTM)N/A
EPS (TTM)-6.60
Earnings DateNov 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est52.50
  • ACCESSWIRE

    Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022

    , to Assume Chairmanship, Effective April 1, 2022SEATTLE, WA / ACCESSWIRE / January 21, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that founding chairman of the board, Fuad El-Hibri, has announced his retirement effective April 1, 2022.

  • ACCESSWIRE

    Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"

    LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / December 15, 2021 / Alligator Bioscience AB ("Alligator") and Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced publication of an article in the December 15, 2021, issue of the peer-reviewed journal, Nature Communications, on the mechanism of action of 4-1BB targeting bispecific antibodies. Nature Communications is an open access, multidisciplinary journal dedicated to publishing high-quality research in all areas of the biological, health,

  • GuruFocus.com

    Towercrest Capital Management Buys Aptevo Therapeutics Inc, PowerShares QQQ Trust Ser 1, ...

    Newtown, PA, based Investment company Towercrest Capital Management (Current Portfolio) buys Aptevo Therapeutics Inc, PowerShares QQQ Trust Ser 1, Invesco S&P 500 Equal Weight ETF, Impel NeuroPharma Inc, Kala Pharmaceuticals Inc, sells Vanguard FTSE Emerging Markets ETF, International Business Machines Corp during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Towercrest Capital Management.

Advertisement
Advertisement